Recent studies suggested HIF-1α could be a therapeutic target of SGLT2 inhibitors in DKD, and multiple molecular mechanisms were investigated but still unclear (Bessho et al., 2019; Cai et al., 2020; Li et al., 2020). Here, HIF1A is linked to diabetic kidney disease.